PDE10A and Dyskinesia: PDE10A inhibitors are a novel class of drug that continues to be explored for a wide range of indications (schizophrenia, Tourette syndrome, childhood-onset fluency disorder, L-dopa-induced dyskinesia in Parkinson’s disease) and may have potential applicability in others.